The study, while exploratory and not sufficiently powered, uncovered some difference in flare rates of BILAG A. The placebo group showed more adjudicated BILAG A flares than the study drug group did, but this difference was also not statistically significant. The study found that the majority of serious adverse events, mostly exacerbated lupus symptoms, occurred during or shortly after the steroid taper. The study also found that the high dose steroids required by the protocol at entry because of the flare design, did not permit sufficient flexibility to individualize treatment according to patient response.
Related Articles
A Yardstick for Lupus
Personal history of the BILAG index
Belimumab Promising for Children with Lupus Nephritis
Belimumab is now FDA approved to treat children aged 5 years and older with active lupus nephritis, providing treatment options for pediatric patients at risk of developing renal damage.
T Cells in Systemic Lupus Erythematosus
Progress toward targeted therapy
Top 12: Research in Systemic Lupus Erythematosus at a Glance
Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.